BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

...2 TRPC5 - Transient receptor potential cation channel subfamily C member 5 V2 receptor - Vasopressin 2 receptor Lauren...
BioCentury | Mar 9, 2018
Emerging Company Profile

Reviving lixivaptan

...Palladio Biosciences Inc. is repurposing lixivaptan as a safer alternative to Jinarc tolvaptan, a competing vasopressin 2 (V2) receptor...
...Phase III testing this year. COMPANY PROFILE Palladio Biosciences Inc. Newtown, Pa. Technology: Lixivaptan, a vasopressin 2 (V2) receptor...
...Staff Writer Chiesi Farmaceutici S.p.A. Otsuka Pharmaceutical Co. Ltd. Palladio Biosciences Inc. Sanofi U.S. Food and Drug Administration (FDA) Glucosylceramide synthase (GCS) Src Vasopressin 2 (V2) receptor Polycystic...
BioCentury | Dec 8, 2017
Clinical News

Otsuka's tolvaptan meets in Phase III for ADKPD

...Orleans and published in the New England Journal of Medicine. A resubmitted NDA for the vasopressin 2 (V2) receptor...
...Ltd., Tokyo, Japan Product: Tolvaptan (Jinarc - EU, Samsca - Japan) Business: Renal Molecular target: Vasopressin 2 (V2) receptor...
...osmolality and specific gravity Status: Phase III data Milestone: PDUFA date (4/24/18) Jennie Walters Jinarc Samsca tolvaptan Otsuka Holdings Co. Ltd. Vasopressin V2 receptor American...
BioCentury | Oct 6, 2017
Clinical News

Vantia's fedovapagon meets in Phase III for nocturia

...second Phase III trial of fedovapagon to treat nocturia. Fedovapagon is a small molecule oral vasopressin 2 (V2) receptor...
...Vantia Therapeutics Ltd. , Southampton, U.K. Product: Fedovapagon (VA106483) (formerly VT483) Business: Genitourinary Molecular target: Vasopressin 2 (V2) receptor...
...who reduce their voids by 50% Status: Phase III data Milestone: NA Elizabeth S. Eaton fedovapagon VA106483 Vantia Therapeutics Ltd. Vasopressin 2 (V2) receptor...
BioCentury | Mar 9, 2017
Clinical News

Noctiva regulatory update

...priorities.” Noctiva is a metered nasal spray containing low-dose desmopressin, a vasopressin analog and selective vasopressin 2 (V2) receptor...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...Otsuka Pharmaceutical Co. Ltd. / Abdi Ibrahim Pharmaceuticals Industry and Trade Co. Ltd. Jinarc tolvaptan Vasopressin 2 (V2) receptor...
BioCentury | Nov 9, 2015
Company News

Otsuka Pharmaceutical sales and marketing update

...guidance recommending Jinarc tolvaptan from Otsuka to treat autosomal dominant polycystic kidney disease (ADPKD). The vasopressin 2 (V2) receptor...
BioCentury | Jun 1, 2015
Clinical News

Jinarc tolvaptan regulatory update

...European Commission approved Jinarc tolvaptan from Otsuka for autosomal dominant polycystic kidney disease (ADPKD). The vasopressin 2 (V2) receptor...
BioCentury | Mar 16, 2015
Clinical News

Jinarc tolvaptan regulatory update

...chronic kidney disease (CKD) at initiation of treatment with evidence of rapidly progressing disease. The vasopressin 2 (V2) receptor...
BioCentury | Mar 9, 2015
Clinical News

Jinarc tolvaptan regulatory update

...tolvaptan to treat autosomal dominant polycystic kidney disease (ADPKD). The company expects to launch the vasopressin 2 (V2) receptor...
Items per page:
1 - 10 of 120